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Treatment of organ donors with catecholamines reduces
acute rejection episodes and improves long-term graft
survival after renal transplantation. The aim of this study was
to investigate the effect of catecholamine pre-treatment on
ischemia/reperfusion (I/R)- and cold preservation injury in rat
kidneys. I/R-injury was induced by clamping the left kidney
vessels for 60 min along with a contralateral nephrectomy.
Cold preservation injury was induced by storage of the
kidneys for 24 h at þ 41C in University of Wisconsin solution,
followed by syngeneic transplantation. Rats were pre-treated
with either dopamine (DA), dobutamine (DB), or
norepinephrine (2, 5, and 10 lg/kg/min, each group)
intravenously via an osmotic minipump for 24 h before
I/R- and cold preservation injury. Pre-treatment with DA (2 or
5 lg/kg/min) and DB (5 lg/kg/min) improved recovery of
renal function after I/R-injury and dose dependently reduced
mononuclear and major histocompatibility complex class
II-positive cells infiltrating the kidney after I/R-injury.
One day after I/R-injury, upregulation of transforming growth
factor (TGF)-b 1 and 2 and phosphorylation of p42/p44
mitogen-activated protein kinases was observed in kidneys
of animals treated with DA or DB. DA (5 lg/kg/min) and DB
(5 lg/kg/min) pre-treatment reduced endothelial cell damage
after 24 h of cold preservation. Only DA pre-treatment
improved renal function and reduced renal inflammation
after 24 h of cold preservation and syngeneic transplantation.
Our results demonstrate a protective effect of pre-treatment
with catecholamines on renal inflammation and function
after I/R- or cold preservation injury. This could help to
explain the potent organoprotective effects of catecholamine
pre-treatment observed in human kidney transplantation.
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Ischemia/reperfusion (I/R)- and cold preservation injury are
major contributors to the development of primary failure
and delayed graft function after renal transplantation.
Despite better HLA-matching, kidneys from cadaver donors
show a poorer graft survival than those from living donors.1,2
It is widely recognized, that not only antigen-dependent
factors, but also antigen-independent factors, such as donor
brain death, cold preservation, and I/R during revasculari-
zation influence allograft survival.
Convincing evidence exists that prolonged cold and warm
ischemia of donor kidneys increase the incidence of delayed
graft function after transplantation,3 leading to decreased
graft and patient survival in the short and long term.4 Tissue
damage and inflammatory response in the kidney caused by
cold preservation and Ischemia/reperfusion (I/R)-injury5 in
the early stage after transplantation may increase the immuno-
genicity of the graft and thus initiate allograft rejection.6
Hence, the development of new strategies to reduce initial
graft damage would reduce the need of re-transplantations
and expand the pool of donor organs.
In two independent retrospective clinical studies,7,8
administration of catecholamines to cadaveric organ donors
reduced the number of acute rejection episodes in the first
month after renal transplantation and markedly improved
long-term graft survival. In a rat model of brain death
characterized by a strong renal inflammation, treatment with
dopamine (DA) reduced renal monocyte infiltration and
major histocompatibility class (MHC) II and P-selectin
expression in renal tissue.9 In vitro, we have recently
demonstrated that catecholamines protect cells against cold
preservation injury either by scavenging of or inhibiting
production of reactive oxygen species.10 The effect of
catecholamine pre-treatment on I/R-injury and cold pre-
servation injury in kidneys was not studied so far. In the
present study, we used a rat model of I/R-injury and a
syngeneic model of renal transplantation to evaluate the effect
of catecholamine pre-treatment on renal function and renal
inflammation after I/R-injury and cold preservation injury.
RESULTS
I/R-injury
Recovery of I/R-injury, induced by clamping of the left
kidney vessels for 60 min, was significantly improved in rats
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pretreated for 24 h with DA 2 mg/kg/min (Po0.05), DA 5 mg/
kg/min (Po0.05), and dobutamine (DB) 5mg/kg/min
(Po0.01) (Figure 1a and b). In contrast, higher dosage of
DA (10 mg/kg/min) and lower dosages of DB (2mg/kg/min)
had no protective effect on kidney function, whereas higher
dosage of DB (10 mg/kg/min) worsened kidney function
before induction of I/R-injury, leading to progressive renal
failure and death of all animals. Norepinephrine (NA) pre-
treatment dose dependently delayed recovery of renal
function after I/R-injury (Figure 1c). Most animals died
between days 2 and 3 after I/R-injury (NA2: 1/8; NA5: 3/8;
NA10: 7/8).
Pre-treatment with catecholamines significantly reduced
renal inflammation 5 days after I/R-injury in a dose-
dependent manner. The amount of ED1- (Figure 2a) and
MHC class II-positive cells (Figure 2b) was significantly
reduced in DA pre-treated rats compared to vehicle pre-
treated rats. Similarly, DB pre-treatment significantly reduced
the number of ED1- (Figure 3a) and MHC class II-expressing
cells (Figure 3b). There was no effect of NA on ED1- and
MHC class II-positive infiltrating cells in kidneys from
surviving animals (data not shown).
On day 1 after I/R-injury, pre-treatment with DA (5mg/kg/
min) or DB (5mg/kg/min) significantly reduced infiltration
of MHC II-positive cells (Figure 4) and showed a tendency to
a reduced number of ED1-positive cells in renal tissue.
Furthermore, there were significantly less TdT-mediated
dUTP nick-end labeling (TUNEL)-positive cells in renal
tissue of animals pre-treated with DA or DB compared to
vehicle-treated rats (Figure 5a–c). Ribonuclease protection
assay of renal tissue harvested 1 day after I/R-injury (Figure 6)
showed a significant upregulation of transforming growth
factor (TGF)-b 1 and TGF-b 2 in animals pre-treated with
DA (TGF-b 1: 0.5570.02; TGF-b 2: 0.2170.02) or DB
(0.5370.04; 0.2270.03), but not in animals pre-treated with
vehicle (0.4170.02; 0.1170.02) when scored by densito-
metry (Po0.05 DA or DB vs vehicle, analysis of variance
(ANOVA)). No changes in tumor necrosis factor-a, inter-
leukin-1, or interferon-g could be detected by ribonuclease
protection assay. Additionally, renal tissue was investigated
for activation (i.e. phosphorylation) of the extracellular
signal-regulated kinase (ERK) p42/p44. Animals pre-treated
with DA or DB (5 mg/kg/min) showed an increase in p42/p44
phosphorylation compared to vehicle-treated rats 1 day after
I/R-injury as detected by densitometry (Po0.05, ANOVA)
(Figure 7). Measurement of malondialdehyde before induc-
tion of I/R-injury and on day 1 after I/R-injury in peripheral
blood as a marker of oxidative stress revealed no differences
between the groups (data not shown).
Cold preservation injury
In kidneys subjected to cold storage in University of
Wisconsin (UW) solution for 24 h, cold preservation injury
was demonstrated by the presence of TUNEL-positive cells.
Serial cryostat sections that were stained either with an anti-
rat endothelial cell monoclonal antibody or by TUNEL
revealed that TUNEL-positive cells were predominantly
found in peritubular capillaries and larger vessels. Although
TUNEL positivity was also detected in tubular cells, the
fluorescence intensity was markedly lower in these cells
compared to endothelial cells (Figure 8). We observed
significant less TUNEL-positive cells after 24 h of cold
preservation in rats pre-treated with DA (5mg/kg/min) or
DB (5mg/kg/min) compared with saline pre-treated rats.
Noradrenaline pre-treatment did not influence cold pre-
servation injury, as quantified by TUNEL-positive cells
(Figure 9). The addition of DB to the preservation solution
without systemic pre-treatment over 24 h significantly
reduced TUNEL-positive cells after 24 h of cold preservation
(Figure 9).
After 24 h of cold preservation and syngeneic transplanta-
tion, only donor pre-treatment with DA (5 mg/kg/min)
significantly improved renal function on the first day after
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Figure 1 | Serum creatinine (mg/dl) after I/R-injury in
uni-nephrectomized rats pre-treated with catecholamines.
(a) Pre-treatment with DA at different doses (DA 2, 5, or
10mg/kg/min). DA pre-treatment with 2 or 5 mg/kg/min significantly
reduces the rise in serum creatinine on day 1 after I/R-injury
(*Po0.05). (b) DB pre-treatment with 5 mg/kg/min significantly
reduces the rise in serum creatinine on day 1 after I/R-injury
(*Po0.01) (ANOVA). Higher dosage of DB (10 mg/kg/min) worsened
renal function before induction of I/R-injury, leading to progressive
renal failure and death of all animals. (c) NA pre-treatment dose
dependently delayed recovery of renal function after I/R-injury. Most
animals died between days 2 and 3 after I/R-injury (NA2: 1/8; NA5:
3/8; NA10: 7/8).
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transplantation (P¼ 0.02) (Figure 10). Pre-treatment with
DA significantly reduced renal infiltration with MHC class II-
and ED1-positive cells 5 days after transplantation (Figures
11 and 12). DB or noradrenaline pre-treatment did not
reduce renal inflammation (data not shown).
DISCUSSION
In the present study, we demonstrate that pre-treatment with
catecholamines reduces I/R-injury and cold preservation
injury in rat kidneys in a substance- and dose-dependent
manner. Renoprotection was observed in organs treated with
low to medium doses of DA or DB, whereas higher doses and
the use of NA had no or even deleterious effects on renal
function and morphology.
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Figure 2 | ED1- and MHC II-positive cells in renal tissue after
DA pre-treatment and I/R-injury. Number of (a) ED1- and
(b) MHC II-positive cells per field of view (original magnification
 40) in renal tissue 5 days after I/R-injury. Pre-treatment with DA
dose dependently reduced infiltration of ED1- and MHC II-positive
cells (ANOVA).
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Figure 3 | ED1- and MHC II-positive cells in renal tissue after DB
pre-treatment and I/R-injury. Number of (a) ED1- and (b) MHC
II-positive cells per field of view (original magnification,  40) in
renal tissue 5 days after I/R-injury. Pre-treatment with DB or
5 mg/kg/min dose dependently reduced infiltration of ED1- and
MHC II-positive cells (ANOVA). All animals pre-treated with DB
10mg/kg/min developed progressive renal failure and died
before day 5.
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Figure 4 | Number of MHC II-positive cells per field of view
(original magnification  40) in renal tissue 1 day after
I/R-injury. Pre-treatment with dobutamine 5 mg/kg/min or DA
5 mg/kg/min reduced infiltration of MHC II-positive cells (*Po0.05
isotonic saline (NaCl) vs dopamine or dobutamine ANOVA).
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Figure 5 | TUNEL-positive cells in renal tissue 1 day after
I/R-injury. Immunohistochemistry for TUNEL-positive cells in renal
tissue harvested 1 day after I/R-injury of animals pre-treated with
(a) vehicle (isotonic saline) , (b) DA (5 mg/kg/min), or (c) DB
(5 mg/kg/min).
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Figure 6 | RNA protection assay of renal tissue harvested 1 day
after I/R-injury of animals pre-treated with isotonic saline, DA
(5 lg/kg/min), or DB (5 lg/kg/min). Treatment with DA or DB led to
an increase in TGF-b 1 and TGF-b 2 expression (n¼ 5 each group,
three animals of each group are shown exemplary). No changes in
interferon-g and tumor necrosis factor-a were detected.
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Low-dose DA administration has been advocated for
many years in oliguric and critically ill patients on the basis of
its action on dopaminergic renal receptors. However, a meta-
analysis of DA on prevention, development, and course of
acute renal failure and mortality in patients treated by
intensive care did not show any beneficial effect.11 Con-
cordantly, authors concluded that ‘dopamine should be
eliminated from routine clinical use for this indication’. A
similar conclusion was drawn by Holmes and Walley,12 who
argued that, in addition to the lack of renal efficacy, DA may
be harmful in patients with critical illnesses. Likewise, the use
of NA in critically ill patients is often fraught with
controversy, as renal dysfunction can occur as a consequence
of its vasoconstrictor effect on renal vascular bed.13
However, there may be clinical situations in which
catecholamines can be safely used to protect kidneys from
injury in severely ill patients. Analysis of two independent
registries, one based on results from cadaveric renal
transplantations at our center and the other on data from
the Eurotransplant International Foundation, revealed that
administration of catecholamines to brain-dead organ
donors reduced the number of acute rejection episodes and
markedly prolonged long-term graft survival without adverse
side effects for the recipients.7,8 Similar to clinical transplan-
tation, we found in vitro that pre-treatment with catechola-
mines also protects cells very effectively against preservation
injury.10 Protection was not receptor-mediated and did not
require de novo protein synthesis. The study demonstrated
that catecholamines prevent cold preservation injury either
by scavenging of reactive oxygen species or by inhibition of
reactive oxygen species generation. Previous studies have
reported catecholamines to possess antioxidative properties
in addition to their pro-oxidative effects.14–18 In a direct
comparison, Miura et al. showed that DB was a more
powerful inhibitor of iron-catalyzed lipid peroxidation than
DA or isoproterenol. This effect was largely achieved by
scavenging of reactive oxygen species. In our study, we were
not able to demonstrate protective effects of DA or DB
treatment regarding a reduction of oxidative stress in the
kidney as measured by malondialdehyde content in peri-
pheral blood, but we can not exclude an effect of scavenging
of reactive oxygen species by catecholamines in this model. In
addition, catecholamines also exert indirect antioxidative
properties by inducing expression of enzymes such as heme
oxygenase-1.19
NaCl Dopamine
pp42/44
p42/44
Figure 7 | Western blot of renal tissue harvested day 1 after
I/R-injury for the MAPKs pp42/44 and p42/44. Treatment with
DA or DB (only DA is shown) led to a significant increase of pp42/44,
that is, phosphorylation (i.e. activation) of p42/44. Unphosphorylated
p42/44 is not changed in renal tissue (Po0.05 isotonic saline vs DA or
DB when scored by densitometry, ANOVA).
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Figure 8 | Influence of cold storage on cell damage in the kidney.
Kidneys from Lewis rats pre-treated with (a) isotonic saline and rats
pre-treated with (b) DB were stored for 24 h in UW solution at 41C.
Serial cryostat sections were stained with (panels to the left) an
anti-rat endothelial cell monoclonal antibody or (panels to the
right) stained by TUNEL. DB pre-treatment (b) reduced the extent of
cold-induced endothelial cell damage. Original magnification,  40.
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Figure 9 | Kidneys from Lewis rats pre-treated with either DB, DA,
or NA in a dose of 5 lg/kg/min for 24 h until explantation were
stored at 41C in UW solution for 24 h. Rats pre-treated with isotonic
saline served as controls. Pre-treatment with DB or DA significantly
protected against cold preservation injury, as quantified by the
presence of TUNEL-positive cells in cold preserved kidneys. Addition
of DB to the preservation solution without systemic pre-treatment
over 24 h significantly reduced TUNEL-positive cells in cold preserved
kidneys. *Po0.01, **Po0.05 (ANOVA).
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Figure 10 | Renal function, as measured by serum creatinine
concentration, after 24 h of cold preservation and syngeneic
transplantation of kidneys from DA (5 lg/kg/min), DB (5 lg/kg/
min), NA (5 lg/kg/min), or vehicle-treated donor rats. Only DA
pre-treatment improved renal function on the first day after
transplantation. (*P¼ 0.03 DA vs isotonic saline, ANOVA).
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It was hypothesized that stimulation of adrenergic and/or
dopaminergic receptors by catecholamines may contribute to
prevention of ischemia-related injury through an alteration
of systemic or renal hemodynamics. However, several lines of
evidence argue against a receptor-mediated mechanism. First,
Schaub et al.9 found that intravenous infusion of DA in a
dose of 10 mg/kg/min over 6 h had no significant effect on
arterial blood pressure and renal blood flow in anesthetized
rats. Second, Schnuelle et al.8 could also show that the
beneficial effect of DA on immediate graft function after
transplantation is independent of systolic and diastolic blood
pressure. Finally, the addition of DB to the preservation
solution for 24 h without previous intravenous administra-
tion to the donor markedly reduced the number of TUNEL-
positive cells in the cold-stored kidney. Thus, it is very
unlikely that adrenergic and/or dopaminergic receptor
stimulation plays a major role in protecting kidneys from
ischemia-related damage.
Recently, the role of mitogen-activated protein kinases
(MAPKs) in I/R-injury was explored by several groups.20–23
MAPKs are a class of protein kinases that include ERK, which
play an important role in the determination of cell survival.
The ERK MAPK family consists of p42 and p44 isoforms,
which are activated by various stimuli including oxidative
stress and several G protein-coupled receptor agonists. It has
recently been shown that DA induces ERK activation and
mitogenesis in proximal tubular cells. The mechanism was
not receptor mediated but required DA uptake into the cells,
its metabolism by monoamine oxidase, and generation of
H2O2, indicating that other catecholamines may also induce
some of its effects through ERK activation.24 The DA d2-like
receptor agonist bromocriptine stimulates p42/44 MAPKs in
proximal tubular epithelial cells, causes mitogenesis via p42/
44 MAPKs in kidney cells, and protects the kidney against I/R
injury in a rat model.25,26 The mitogenic activity of DA could
play a key role in normal cell growth and repair processes.
This might be of importance in our model as proliferation of
tubular cells is essential for recovery from acute renal
failure.27 In myocardial28–30 and renal20,23,31–33 cell damage,
activation of ERKs is considered to be a sign of tissue
regeneration and protection. In agreement with these results,
we found an increase in ERK activation in animals
pre-treated with DA and DB, which were protected against
I/R-injury.
DA- and DB-treated animals showed an increased
expression of TGF-b 1 day after I/R-injury. A recent study
has shown an increase in TGF-b secretion in pituitary cells
after stimulation with DA or bromocriptine.34 TGF-b is a
polypeptide growth factor playing an important role in
wound healing and tissue regeneration.35 TGF-b inhibits
proliferation of renal proximal tubule cells in vitro and
stimulates extracellular matrix synthesis, cell clustering,
tubulogenesis, and apoptosis.36,37 Previous studies have
shown rapid and prolonged upregulation of TGF-b primarily
in regenerating proximal tubules after renal ischemia,
indicating a potential role for TGF-b in the regenerating
kidney.38,39 Basile et al.40 demonstrated a spatial and
temporal relationship with TGF-b and several extracellular
matrix-related genes post-ischemia, which was partially
inhibited by the administration of a TGF-b-neutralizing
antibody in vivo, showing that TGF-b may participate in
renal regenerating by promoting extracellular matrix synth-
esis and providing newly formed proximal tubule cells a solid
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Figure 11 | Donor DA pre-treatment significantly reduced MHC
class II- and ED1-positive cells in syngenically transplanted
kidneys 5 days after transplantation (*Po0.0001 DA vs isotonic
saline, unpaired t-test).
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Figure 12 | Immunohistology of donor kidneys pre-treated with
(panel to the right) DA or (panel to the left) isotonic saline 5 days
after isogeneic transplantation. Note the strong infiltrates found in
rats pre-treated with isotonic saline in (a) glomerular and (b) tubular
areas, and in (c) larger vessels (c). Original magnification  40.
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substrate for adhesion and migration. Furthermore, genotype
analysis of donor and recipients of kidney transplants
revealed an association of low TGF-b production with an
elevated risk for early rejection and worse graft function at 4
years.41 However, other studies failed to identify a prominent
role for TGF-b in renal repair after I/R-injury.42
In contrast to post-ischemic acute renal failure, only DA,
but not DB and NA treatment of donor rats improved
immediate graft function after 24 h of cold preservation and
syngeneic transplantation. These data strikingly correlate to
those of Schnuelle et al.,43 who found that DA was the only
catecholamine that improved initial graft function after
kidney transplantation. All other adrenergic derivatives were
ineffective with respect to normalizing serum creatinine after
controlling for confounding factors by multivariate Cox
regression. The observed differences in efficacy of catechol-
amines both in vitro and in vivo cannot be explained on the
basis of our results and need to be investigated in future
studies.
Systemic pre-treatment of organ donors or pre-treatment
of donor organs by improved preservation solutions is
gaining more and more interest. Preventing the initial tissue
damage, originating from donor brain death, cold preserva-
tion, or I/R-injury, by pharmacological pre-treatment, may
reduce immunogenicity of the graft6 and thus improve initial
function and prolong long-term survival.44–49 Indeed, donor
DA treatment has been shown, in a retrospective analyses, to
increase long-term graft survival in humans7,8 and in an
experimental rat model, to improve short- and long-term
outcome after prolonged cold storage and subsequent
allogeneic kidney transplantation.50 The attractiveness of
the concept of pharmacological pre-treatment of organ
donors is further underlined by the fact that it is not
associated with any costs and side effects for the recipients. A
randomized prospective clinical trial, investigating the effect
of DA pre-treatment of brain-dead organ donors on short-
and long-term renal graft function is currently under
progress.
In summary, we have shown for the first time that pre-
treatment with catecholamines reduces both I/R and cold
preservation injury in rat kidneys. The use of catecholamines,
when administered in higher doses, is limited by severe
hemodynamic side effects. Newly synthesized chemically
modified derivatives of catecholamines lacking sympathoa-
drenergic properties are currently under investigation and
may prove beneficial for pre-treatment of organ donors.
MATERIALS AND METHODS
Animals
Inbred male Lewis (LEW, RT11) rats weighing 220–250 g were
obtained from Harlan-Winkelmann (Borchen, Germany). Animals
were kept under standard conditions and fed standard rodent chow
and water ad libitum. All procedures were performed according to
the guidelines of the American Physiological Society and were
approved by the local authorities (Regierungspra¨sidium Karlsruhe
AZ: 35-9185.81/166/01).
Experimental protocol
All surgical procedures were performed under general
anesthesia with ketamine (100 mg/kg body weight intraperitoneal;
CP-Pharma, Burgdorf, Germany) and xylazine (5 mg/kg body
weight intraperitoneal; Rompuns Bayer, Leverkusen, Germany).
For pre-treatment, an osmotic minipump (Alzet 2ML1) was
implanted subcutaneously in the animals back. A catheter attached
to the pump was placed in the left femoral vein and the pre-
treatment solution was administered for 24 h (mean pumping rate
10 ml/h).
In the model of I/R-injury, Lewis rats received pre-treatment
with either DA (2, 5, or 10 mg/kg/min), DB (2, 5, or 10 mg/kg/min),
NA (2, 5, or 10mg/kg/min), or isotonic saline (control) (n¼ 8 each
dosage) for 24 h. After the pre-treatment period, the pumps were
removed and the rats underwent right nephrectomy. These kidneys
were snap frozen in liquid nitrogen and stored at 801C for further
analysis. Before induction of ischemia, animals received 100 IU
heparin/kg intravenously to prevent renal arterial thrombosis. The
vessels of the remaining left kidney were clamped for 60 min. After
removal of the clamps, the abdominal wall was closed with
continuous sutures, and the animals were housed as described
above.
To assess cold preservation injury, Lewis donor rats were pre-
treated intravenously with either DA (5 mg/kg/min), DB (5mg/kg/
min), NA (5 mg/kg/min), or isotonic saline (n¼ 5 each group) as
described above. After the pre-treatment period, both donor kidneys
were explanted, flushed with 1 ml UW solution each, and stored for
24 h at þ 41C in UW solution. After cold preservation, one kidney
of each group was snap frozen in liquid nitrogen for further TUNEL
staining to show apoptotic cells. Next, kidneys were transplanted
syngeneically in bilaterally nephrectomized Lewis rats using
standard microsurgical techniques. Renal perfusion was restored in
all cases after 25 min.
In all animals, blood samples for measurement of serum
creatinine (Dimensions, Dade-Behring, Frankfurt, Germany) were
obtained on days 0, 1, 3, and 5 after induction of I/R-injury or after
isogeneic transplantation. On day 5, all animals were killed, and
kidneys were harvested and frozen in liquid nitrogen. Additionally,
kidneys of animals pre-treated with DA 5 mg/kg/min, DB (5 m/kg/
min), or isotonic saline were harvested on day 1 after I/R-injury
(n¼ 5 each group).
Immunohistochemistry
Serial cryostat sections (3–5 mm) were either fixed in acetone/
methanol (70/30%) or in paraformaldehyde (2.5%) for immuno-
histochemical or TUNEL staining. For immunohistology, sections
were incubated with specific mouse-anti-rat antibodies. Then,
sections were stained with biotinylated horse-anti-mouse antibody
using the avidin-biotinylated-peroxidase immunolabeling method
(Vector Laboratories Inc., Burlingame, CA, USA) and counter-
stained with hematoxylin. Cell populations and cell surface marker
were assessed using monoclonal antibodies to macrophages and
monocytes (ED1), MHC class II (F17-23-2), and endothelial cells
(JG12, 1:10). Anti-endothelial antibodies were kindly provided by
Professor D Kerjaschki (Vienna, Austria), and all other antibodies
were purchased from Serotec Ltd (Kidlington, UK). Negative
controls included omission of the first antibody or murine control
immunoglobulin. Positive cells are expressed as mean7s.e.m. of
cells/field of view (c/FV). More than 20 fields of view/section were
evaluated at  400.
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TUNEL staining to show apoptotic cells was performed
according to the manufacturer’s instructions (Roche diagnostics,
Mannheim, Germany). In brief, tissue sections were washed twice
with phosphate-buffered saline after fixation and incubated for
15 min in permeabilization solution (0.1 mM sodium citrate) at
701C. Hereafter, the sections were extensively washed and incubated
for 30 min at 371C with 50 ml of reaction mixture in humid
chambers. In each experiment and for each staining, a negative
control was included, by omitting dUTP transferase from the
reaction mixture. TUNEL-positive cells were detected by immune-
fluorescence microscopy using a fluorescein isothiocyanate filter. In
the same experiment, TUNEL staining on paraffin-embedded renal
tissue was performed using an anti-fluorescein antibody conjugated
to peroxidase. TUNEL-positive cells were visualized by addition of
diaminobenzidine tetrahydrochloride substrate (Vector Laboratories
Inc., Burlingame, CA, USA).
RNase protection assay
Total RNA was isolated from whole kidneys harvested 24 h after
using TRIzol Reagent (Invitrogen, karlsruhe, Germany). RNA was
precipitated with isopropanol, washed with 70% ethanol, and
subjected to RNase protection assays using BD RiboQuantTM multi-
probe sets (RCK-1 and RCK-3; BD Biosciences, San Jose, CA, USA;
Instruction manual is available at bdbiosciences.com, BD Bio-
sciences, 2002. BD RiboQuantTM Multi-Probe RNase Protection Assay
System (Instruction Manual)) following the supplier’s instructions.
The gels were dried and subjected to autoradiography. The RNA
transcripts were identified by appropriate length of the protective
fragments. In each of the template sets, the housekeeping genes L32
and glyceraldehyde-3-phosphate dehydrogenase were included to
control for equal loading.
Western blot analysis
Tissue was homogenized and lysed in buffer (10 mM Tris, 2%
sodium dodecyl sulfate, 0.5% b-mercaptoethanol, all from Sigma-
Aldrich (St Louis, MO, USA). Protein concentrations were measured
using Coomassie-Reagent (Pierce, Rockford, IL, USA). The samples
were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and semidry blotted on a polyvinylidine difluoride
membrane (Roche Diagnostics, Mannheim, Germany). The mem-
brane was incubated overnight in 5% milk powder in Tris-buffered
saline (10 mM Tris-HCl, pH 8.0, 150 mM NaCl) solution. Thereafter,
the blot was incubated for 1 h with a polyclonal antibody against
phospho-p42/p44 (Santa Cruz, Heidelberg. Germany), followed by
incubation with an appropriate horseradish peroxidase secondary
antibody (Santa Cruz, Heidelberg, Germany). Proteins were
visualized using enhanced chemoluminescence technology accord-
ing to the manufacturer’s instruction (Pierce, Rockford, IL,
USA). To confirm equal protein loading, membranes were stripped
with 62.5 mM Tris-HCl, 2% sodium dodecyl sulfate, and 100 mM
b-mercaptoethanol, and incubated with a polyclonal antibody
against p42/p44 (Santa Cruz, Heidelberg, Germany). Where
indicated, the Western blots were subjected to densitometric analysis
using Scion Image software.
Malondialdehyde
Plasma malondialdehyde was measured by enzymatic
detection, according to the method described by Esterbauer and
Cheeseman.51
Statistical analysis
Data are shown as means7s.e.m. For comparison of means between
different groups, ANOVA with Tukey’s option for multiple
comparison was applied (StatsDirect version 2.2.2). Statistical
significance was defined as a P-value o0.05.
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